Firstly, we utilized the ‘Biomarker evaluation’ module from TIDE (Tumor Immune Dysfunction and Exclusion) (http://tide.dfci.harvard.edu/setquery/, accessed on 13 September 2022) to determine the performance of ACAP1 expression in predicting the ICT response. The gene discussed is ACAP1; the disease is neoplasm.